Comparative efficacy of leukotriene modifier and inhaled corticosteroids in the complex treatment of steroid-naive patients with bronchial asthma combined with chronic obstructive pulmonary disease with neutrophilic type of inflammation

Authors

DOI:

https://doi.org/10.14739/2310-1210.2021.4.229508

Keywords:

bronchial asthma, chronic obstructive lung disease, treatment

Abstract

The aim: to compare the efficacy and tolerability of the leukotriene modifier and inhaled corticosteroids in combination with long-acting β2-agonist formoterol in steroid-naive patients with asthma combined with COPD with neutrophilic inflammation.

Materials and methods. After obtaining the written consent, 30 patients with asthma combined with COPD and a number of blood neutrophils >4000/μl were randomized (1:1): group I – received a fixed combination of budesonide/formoterol 160/4.5 μg/1 inhalation twice daily as a basic therapy; group II – montelukast 1 tab. (10 mg) once daily and inhalation of formoterol 12 mcg/dose twice daily. The duration of therapy was 12 weeks. General clinical methods, asthma control questionnaires, COPD questionnaire, physical tolerance evaluation (6-minute walk test), pulmonary function tests, quality of life assessment were performed to all the patients before and after the treatment course studied.

Results. The combination of budesonide/formoterol improved clinical symptoms – significantly (P < 0.05) increased the total ACT score, decreased the average ACQ score, shortness of breath (mMRC scale), COPD symptoms. PFT indices were improved significantly (P < 0.05), bronchoobstruction at the level of large, medium and small bronchi was significantly reduced. Physical tolerance was significantly improved. There were no statistically significant dynamics of the studied indices in patient group II. The patients of both groups showed a tendency to improve their quality of life. In patients of I group, there was a significant decrease in activity limitations and the total SGRQ score.

Conclusions. The combination of inhaled corticosteroid/formoterol has proven to be more effective than the leukotriene modifier or formoterol in steroid-naive patients with asthma combined with COPD and neutrophilic inflammation.

Author Biographies

Yu. I. Feshchenko, SI “National Institute of Phthisiology and Pulmonology named after F. H. Yanovskyi NAMS of Ukraine”, Kyiv

MD, PhD, DSc, Professor, Academician of NAMS of Ukraine, Director

L. O. Yashyna, SI “National Institute of Phthisiology and Pulmonology named after F. H. Yanovskyi NAMS of Ukraine”, Kyiv

MD, PhD, DSc, Professor, Head of the Department of Diagnostic, Therapy and Clinical Pharmacology of Lung Diseases

V. I. Ihnatieva, SI “National Institute of Phthisiology and Pulmonology named after F. H. Yanovskyi NAMS of Ukraine”, Kyiv

PhD, Senior Researcher of the Department of Diagnostic, Therapy and Clinical Pharmacology of Lung Diseases

M. O. Polianska, SI “National Institute of Phthisiology and Pulmonology named after F. H. Yanovskyi NAMS of Ukraine”, Kyiv

MD, PhD, Senior Researcher of the Department of Diagnostic, Therapy and Clinical Pharmacology of Lung Diseases

S. H. Opimakh, SI “National Institute of Phthisiology and Pulmonology named after F. H. Yanovskyi NAMS of Ukraine”, Kyiv

MD, PhD, Senior Researcher of the Department of Diagnostic, Therapy and Clinical Pharmacology of Lung Diseases

I. V. Zvol, SI “National Institute of Phthisiology and Pulmonology named after F. H. Yanovskyi NAMS of Ukraine”, Kyiv

MD, PhD, Senior Researcher of the Department of Diagnostic, Therapy and Clinical Pharmacology of Lung Diseases

S. M. Moskalenko, SI “National Institute of Phthisiology and Pulmonology named after F. H. Yanovskyi NAMS of Ukraine”, Kyiv

MD, PhD, Senior Researcher of the Department of Diagnostic, Therapy and Clinical Pharmacology of Lung Diseases

H. L. Humeniuk, SI “National Institute of Phthisiology and Pulmonology named after F. H. Yanovskyi NAMS of Ukraine”, Kyiv

MD, PhD, DSc, Senior Researcher of the Department of Diagnostic, Therapy and Clinical Pharmacology of Lung Diseases

N. A. Vlasova, SI “National Institute of Phthisiology and Pulmonology named after F. H. Yanovskyi NAMS of Ukraine”, Kyiv

MD, Head of the Department of Differential Diagnostic of Tuberculosis and Non-specific Lung Diseases

L. A. Halai, SI “National Institute of Phthisiology and Pulmonology named after F. H. Yanovskyi NAMS of Ukraine”, Kyiv

MD, Pulmonologist of the Department of Differential Diagnostic of Tuberculosis and Non-specific Lung Diseases

References

Hosseini, M., Almasi-Hashiani, A., Sepidarkish, M., & Maroufizadeh, S. (2019). Global prevalence of asthma-COPD overlap (ACO) in the general population: a systematic review and meta-analysis. Respiratory Research, 20(1), Article 229. https://doi.org/10.1186/s12931-019-1198-4

Yanagisawa, S., & Ichinose, M. (2018). Definition and diagnosis of asthma-COPD overlap (ACO). Allergology International, 67(2), 172-178. https://doi.org/10.1016/j.alit.2018.01.002

Halpin, D. (2020). What Is Asthma Chronic Obstructive Pulmonary Disease Overlap? Clinics in Chest Medicine, 41(3), 395-403. https://doi.org/10.1016/j.ccm.2020.06.006

Tochino, Y., Asai, K., Shuto, T., & Hirata, K. (2017). Asthma-COPD overlap syndrome-Coexistence of chronic obstructive pulmonary disease and asthma in elderly patients and parameters for their differentiation. Journal of General and Family Medicine, 18(1), 5-11. https://doi.org/10.1002/jgf2.2

Gibson, P. G., & Foster, P. S. (2019). Neutrophilic asthma: welcome back! The European Respiratory Journal, 54(5), Article 1901846. https://doi.org/10.1183/13993003.01846-2019

Yang, X., Li, H., Ma, Q., Zhang, Q., & Wang, C. (2018). Neutrophilic Asthma Is Associated with Increased Airway Bacterial Burden and Disordered Community Composition. BioMed Research International, 2018, Article 9230234. https://doi.org/10.1155/2018/9230234

Ray, A., & Kolls, J. K. (2017). Neutrophilic Inflammation in Asthma and Association with Disease Severity. Trends in Immunology, 38(12), 942-954. https://doi.org/10.1016/j.it.2017.07.003

Thomson, N. C. (2016). Novel approaches to the management of noneosinophilic asthma. Therapeutic Advances in Respiratory Disease, 10(3), 211-234. https://doi.org/10.1177/1753465816632638

Global Initiative for Asthma. (2020). Global Strategy for Asthma Management and Prevention (Updated 2020). https://ginasthma.org/wp-content/uploads/2020/06/GINA-2020-report_20_06_04-1-wms.pdf

Feshchenko, Yu. I., Yashyna, L. O., Havrysiuk, V. K., Krakhmalova, O. O., Matiukha, L. F., Mostovyi, Yu. M., Pertseva, T. O., Polianska, M. O., Rekalova, O. M., Ostrovskyi, M. M., Zaikov, S. V., Konopkina, L. I., & Konstantynovych, T. V. (2020). Adaptovana klinichna nastanova, zasnovana na dokazakh. Bronkhialna astma [Adapted evidence-based clinical guideline. Bronchial asthma]. Natsionalna akademiia medychnykh nauk Ukrainy. [in Ukrainian].

Ministry of Health of Ukraine. (2013, October 08). Pro zatverdzhennia ta vprovadzhennia medyko-tekhnolohichnykh dokumentiv zi standartyzatsii medychnoi dopomohy pry bronkhialnii astmi [On Approval and implementation of the technological medical documents on standardizing the management of bronchial asthma (No. 868)]. https://zakon.rada.gov.ua/rada/show/v0868282-13#Text

Ministry of Health of Ukraine. (2013, June 27). Pro zatverdzhennia ta vprovadzhennia medyko-tekhnolohichnykh dokumentiv zi standartyzatsii medychnoi dopomohy pry khronichnomu obstruktyvnomu zakhvoriuvanni lehen [On Approval and implementation of the technological medical documents on standardizing the management of chronic obstructive pulmonary disease (No. 555)]. https://zakon.rada.gov.ua/rada/show/v0555282-13#Text

Esteban-Gorgojo, I., Antolín-Amérigo, D., Domínguez-Ortega, J., & Quirce, S. (2018). Non-eosinophilic asthma: current perspectives. Journal of Asthma and Allergy, 11, 267-281. https://doi.org/10.2147/JAA.S153097

Maselli, D. J., & Hanania, N. A. (2019). Management of asthma COPD overlap. Annals of Allergy, Asthma, & Immunology, 123(4), 335-344. https://doi.org/10.1016/j.anai.2019.07.021

Bonini, M., & Usmani, O. S. (2015). The role of the small airways in the pathophysiology of asthma and chronic obstructive pulmonary disease. Therapeutic Advances in Respiratory Disease, 9(6), 281-293. https://doi.org/10.1177/1753465815588064

Feshchenko, Y. I., Iashyna, L. O., Ignatieva, V. I., Polianska, M. O., Nazarenko, K. V., Gumeniuk, G. L., Moskalenko, S. M., Opimakh, S. G., & Zvol, I. V. (2019). Osoblyvosti bronkhialnoi astmy z neitrofilnym typom zapalennia [Features of bronchial asthma with neutrophilic inflammation]. Astma ta alerhiia, (3), 35-40. https://doi.org/10.31655/2307-3373-2019-3-35-40 [in Ukrainian].

Global Initiative for Chronic Obstructive Lung Disease. (2021). Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. (2021 report). https://goldcopd.org/2021-gold-reports/

Downloads

Published

2021-07-01

How to Cite

1.
Feshchenko YI, Yashyna LO, Ihnatieva VI, Polianska MO, Opimakh SH, Zvol IV, Moskalenko SM, Humeniuk HL, Vlasova NA, Halai LA. Comparative efficacy of leukotriene modifier and inhaled corticosteroids in the complex treatment of steroid-naive patients with bronchial asthma combined with chronic obstructive pulmonary disease with neutrophilic type of inflammation. Zaporozhye Medical Journal [Internet]. 2021Jul.1 [cited 2024Dec.26];23(4):516-23. Available from: http://zmj.zsmu.edu.ua/article/view/229508

Issue

Vol. 23 No. 4 (2021)

Section

Original research

License

Authors who publish with this journal agree to the following terms:

    1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.  Лицензия Creative Commons
    2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
    3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access)